Marinus (MRNS)

Marinus (MRNS) Stock Price & Analysis


MRNS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.47 - $9.82
Previous Close$9.13
Average Volume (3M)672.70K
Market Cap
Enterprise Value$333.80M
Total Cash (Recent Filing)$199.20M
Total Debt (Recent Filing)$71.50M
Price to Earnings (P/E)-15.1
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding50,547,986
10 Day Avg. Volume728,564
30 Day Avg. Volume672,703
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)4.78
Price to Sales (P/S)123.49
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-71.26
Enterprise Value/Gross Profit19.60
Enterprise Value/Ebitda-14.90
Price Target Upside148.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $3.46 and its highest was $9.82 in the past 12 months.
    What is Marinus’s market cap?
    Currently, no data Available
    When is Marinus’s upcoming earnings report date?
    Marinus’s upcoming earnings report date is Aug 10, 2023 which is in 62 days.
      How were Marinus’s earnings last quarter?
      Marinus released its earnings results on May 11, 2023. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.731 by $0.061.
        Is Marinus overvalued?
        According to Wall Street analysts Marinus’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Marinus pay dividends?
          Marinus does not currently pay dividends.
          What is Marinus’s EPS estimate?
          Marinus’s EPS estimate is -$0.72.
            How many shares outstanding does Marinus have?
            Marinus has 50,547,985 shares outstanding.
              What happened to Marinus’s price movement after its last earnings report?
              Marinus reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.731. Following the earnings report the stock price went down -3.34%.
                Which hedge fund is a major shareholder of Marinus?
                Among the largest hedge funds holding Marinus’s share is Woodline Partners LP. It holds Marinus’s shares valued at 11M.


                  Marinus Stock Smart Score

                  The Marinus stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.


                  Top 5 ETFs holding MRNS

                  Market Value
                  Smart Score
                  iShares Biotechnology ETF
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Invesco Nasdaq Biotechnology ETF
                  Up to five ETFs with an Outperform Smart Score that hold MRNS. The ETFs are listed according to market value of MRNS within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Acer Therapeutics
                  Selecta Biosciences
                  Akebia Therapeutics
                  Akari Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis